SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEssentra Regulatory News (ESNT)

Share Price Information for Essentra (ESNT)

Share Price is delayed by 15 minutes
Get Live Data
85.60    1.60 (1.90%)
Bid:
85.40
Ask:
86.00
Spread: 0.60 (0.703%)
Market Cap: £239.85m
ESNT Live PriceLast checked at - London Stock Exchange

Intraday Essentra Share Chart

Acquisition of Device Technologies

17 Dec 2025 07:00

RNS Number : 8392L
Essentra plc
17 December 2025
 

ESSENTRA PLC

("Essentra", the "Group" or the "Company")

ACQUISITION OF DEVICE TECHNOLOGIES LLC

Essentra plc, a leading global provider and manufacturer of essential components and solutions, is pleased to announce the acquisition of Device Technologies LLC. ("Device Technologies"), a family-owned, US-based designer, manufacturer and distributor of specialty cable protection devices for an initial cash consideration of $6.7m (the "acquisition").

Based in Massachusetts, Device Technologies has over 40 years of operational history and a strong track record of growth. Essentra has extensive knowledge of working with Device Technologies, through a successful distribution partnership spanning a number of years. The company designs, manufactures and distributes a broad range of specialty cable protection devices such as grommet edging, shielding gaskets and cable sleeving, which complement Essentra's existing product expertise. With a well-established presence in the U.S. and exposure to Essentra's target customer sectors, including energy transformation, transportation and general industrial markets, Device Technologies provides a strong adjacency to Essentra's electronics, cable management and access hardware product ranges.

The acquisition is fully aligned with the Group's disciplined approach to inorganic growth, both in terms of strategic alignment and in delivering financial returns. The acquisition represents a strategic in-sourcing of manufacturing capabilities, deepens product knowledge, and extends Essentra's manufactured product offering. In line with the Group's acquisition criteria, Device Technologies is expected to deliver attractive revenue synergies through cross-selling opportunities into EMEA and APAC where Device Technologies today has limited presence.

The total consideration comprises an initial cash payment of $6.7m and deferred contingent cash consideration1 of up to $1.2m, on a cash-free, debt-free basis. For the year ended 31 December 2024, Device Technologies generated revenues of approximately $6.5m. The initial consideration represents an acquisition multiple of 6.6x EBITDA for the last-twelve-months to June 2025, which is within Essentra's targeted range. A return on invested capital2 of 15% is anticipated within three years, in keeping with the Group's acquisition criteria.

Post-acquisition, Essentra's balance sheet remains strong, with FY25 pro forma net debt position expected to be below 1.5x.

 

Scott Fawcett, CEO of Essentra, said:

"I am delighted to announce the acquisition of Device Technologies, which strengthens Essentra's product portfolio, expands our presence in the Americas, and unlocks further cross-selling opportunities across the Group. This transaction is a clear example of our inorganic growth strategy in action, leveraging our strong balance sheet to drive product expansion and market share gains. We are pleased to welcome another high-quality business, with a strong track record of growth into the Essentra Group, which will be accretive to both earnings and margins and support our strategy for long-term sustainable value creation."

 

 

Enquiries

Essentra plc

Rowan Baker, Chief Financial Officer

Claire Goodman, Head of Investor Relations

Tel: +44 (0)1908 359100

FTI Consulting

Richard Mountain

Ariadna Peretz

FTI_essentra@fticonsulting.com

Tel: +44 (0)20 3727 1340

Notes

1. Deferred contingent consideration is subject to certain performance conditions over a one-year period.

2. Return on Invested Capital is calculated as adjusted operating profit expressed as a percentage of invested capital. Invested capital is defined as initial consideration and deferred contingent consideration, plus capex investment, and associated acquisition transaction fees.

 

More information on Device Technologies Inc. can be found on its website at: www.devicetech.com

 

About Essentra plc

Essentra plc is a leading global provider of essential components and solutions, focusing on the manufacture and distribution of plastic injection moulded, vinyl dip moulded and metal items.

Headquartered in the United Kingdom, Essentra's global network extends to 28 countries worldwide and includes c.3,000 employees, 14 manufacturing facilities, 26 distribution centres and 37 sales & service centres serving c.64,000 customers with a rapid supply of low cost but essential products for a variety of applications in industries such as equipment manufacturing, automotive, fabrication, electronics, medical and renewable energy. For further information, please visit www.essentraplc.com

LEI: 5493007MOZNA03BVNE96

Cautionary forward-looking statement

These results contain forward-looking statements based on current expectations and assumptions. Various known and unknown risks, uncertainties and other factors may cause actual results to differ from future results or developments expressed or implied from the forward-looking statements. Each forward-looking statement speaks only as of the date of this document. The Company accepts no obligation to revise or update these forward-looking statements publicly or adjust them to future events or developments, whether as a result of new information, future events or otherwise, except to the extent legally required.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQBCBDDUGBDGUL
Date   Source Headline
10th Jun 20269:47 amRNSHolding(s) in Company
1st Jun 20267:00 amRNSTotal Voting Rights
29th May 20262:32 pmRNSTransaction in Own Shares
21st May 202610:55 amRNSResult of AGM
20th May 20267:00 amRNSAcquisition of Boteco Srl
20th May 20267:00 amRNS2026 AGM Trading Update
14th May 20265:15 pmRNSDirector/PDMR Shareholding
12th May 20267:03 amRNSTransaction in Own Shares
1st May 202612:17 pmRNSTotal Voting Rights
29th Apr 20268:12 amRNSTransaction in Own Shares
28th Apr 20263:25 pmRNSDirector/PDMR Shareholding
24th Apr 20263:30 pmRNSDirector/PDMR Shareholding
22nd Apr 20268:15 amRNSTransaction in Own Shares
21st Apr 20264:09 pmRNSDirector/PDMR Shareholding
17th Apr 20267:52 amRNSHolding(s) in Company
15th Apr 202610:06 amRNSDirector/PDMR Shareholding
15th Apr 20268:24 amRNSTransaction in Own Shares
15th Apr 20268:18 amRNSHolding(s) in Company
9th Apr 20268:24 amRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSHolding(s) in Company
1st Apr 20264:45 pmRNSDirector/PDMR Shareholding
1st Apr 20263:21 pmRNSDirector/PDMR Shareholding
1st Apr 20263:15 pmRNSTransaction in Own Shares
1st Apr 20263:08 pmRNSTotal Voting Rights
30th Mar 20262:00 pmRNSAnnual Financial Report
24th Mar 202610:05 amRNSTransaction in Own Shares
24th Mar 20268:17 amRNSHolding(s) in Company
19th Mar 20268:43 amRNSDirector/PDMR Shareholding
17th Mar 20261:41 pmRNSDirector/PDMR Shareholding
17th Mar 202610:30 amRNSDirectorate change
17th Mar 202610:28 amRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSResults for the Full Year Ended 31 December 2025
17th Mar 20267:00 amRNSResults for the Full Year Ended 31 December 2025
16th Mar 20269:40 amRNSTransaction in Own Shares
16th Mar 20269:40 amRNSTransaction in Own Shares
13th Mar 202612:00 pmRNSCompany Secretary Change
9th Mar 20269:00 amRNSNotice of Full Year 2025 Results
9th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTotal Voting Rights
26th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
23rd Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:58 amRNSHolding(s) in Company
19th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 202612:20 pmRNSHolding(s) in Company
17th Feb 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.